ClinicalTrials.gg
CompletedNCT03441789Updated Mar 14, 2019Results posted

Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis

A Phase 4 interventional study of Enstilar and Vehicle in Plaque Psoriasis, sponsored by L.H. Kircik, M.D.. Completed at 4 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-14.

Sponsored by L.H. Kircik, M.D. · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Sep 2017, registered Feb 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.

Enrollment
499th of 673
28 · median 77
Started
2017
with 49 others
Phase 4
117 of 764
15 open now
Registered
480th of 764
by date

Among the 764 studies in Psoriasis with a site in United States, this one is the 499th largest by enrollment of the 673 interventional ones that give a count, is one of 50 that started in 2017, is one of 117 in phase 4, and was the 480th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 764 studies in Psoriasis with a site in United States, or all of them as a file.
02

Study summary

This study seeks to show whether there is a benefit of prescribing Enstilar with Otezla in the treatment of patients with moderate plaque type psoriasis. Subjects will be randomized to study treatment at a 1:1 ratio of Otezla plus Enstilar foam versus Otezla plus vehicle foam.

Read the detailed description

Approximately 50 subjects from 4 sites will be enrolled in this investigator-blind study. Subjects will be randomized 1:1 to Otezla plus Enstilar foam or Otezla plus vehicle foam and all adverse events and concomitant medications will be recorded.

Subjects will attend a screening visit/baseline visit and those with plaque-type psoriasis who have been started on commercial Otezla in the last 7 days will be randomized to study treatment as outlined above.

Enstilar or the vehicle will be initiated for the first 4 weeks and then Otezla will be continued as monotherapy for the next 8 weeks. Enstilar or the vehicle will be reinitiated for the last 4 weeks of the study. Total study period is 16 weeks and study visits will occur as follows: screening/baseline, week 1, 2, 3, 4, week 12, and week 16. Study assessments at each visit will be PASI, BSA, PGA, Itch VAS, DLQI, and standard medical assessments. There will be standard medication/treatment and washout periods.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

I. Outpatient, male or female subjects of any race, 18 years of age or higher. Female subjects of must have a (-)UPT (urine pregnancy test) result at within 7 days of the first dose of study drug and practice a reliable method of throughout the study;

A female is considered of childbearing potential unless she is:

  • ≥ 5 years of age, without a uterus and/or both ovaries; or has been surgically sterile for ≥ 6 moths.

Reliable methods of contraception are:

  • hormonal methods or IUD (intrauterine device) in use ≥ 90 days prior to study drug administration, barrier methods plus spermicide in use ≥ 14 days prior, or vasectomized partner.

[Exception: Female subjects of CBP (child bearing potential) who are not sexually active are not required to practice a reliable method of contraception and may be enrolled at the Investigator's discretion provided they are counseled to remain sexually inactive for the duration of the study and understand the risks involved in getting pregnant during the study.] ii. Subjects with moderate plaque type psoriasis who have been started on commercial Otezla within the last 10 days.

iii. Physician Global Assessment (PGA) score of 3. iv. Able to understand study requirements and sign /HIPAA forms.

Exclusion criteria

Exclusion Criteria:

I. Female subjects who are pregnant, breast-feeding, or who are of and not practicing a reliable method of , or male subjects planning a pregnancy with their spouse or partner while in the study.

ii. History of hypercalcemia or vitamin D toxicity or history of significant renal or hepatic disease iii. Patients with guttate, erythrodermic, or pustular psoriasis iv. Serious skin condition (other than psoriasis) or uncontrolled medical condition (in the opinion of the investigator).

v. Skin conditions (e.g.eczema) other than psoriasis that may interfere with evaluations of psoriasis.

vi. Known to Enstilar Foam or any of its components. vii. Current drug or alcohol abuse (Investigator opinion). viii. Subject unable to commit to all the assessments required by the protocol. ix. Current enrollment in another clinical study and treatment with another experimental drug or approved therapy for experimental use within 30 days prior to the Screening Visit.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Otezla plus Enstilar foam

    Subjects randomized to this group will receive Otezla 30mg by mouth twice daily and Enstilar applied to affected areas once daily

    Drug: Enstilar · Drug: Otezla

  • Placebo comparator
    Otezla plus vehicle foam

    Subjects in this group will take Otezla 30mg by mouth twice daily and vehicle foam applied to affected areas once daily

    Drug: Vehicle · Drug: Otezla

Interventions

  • DrugEnstilar

    Enstilar foam applied to affected areas daily

    Also known as: calcipotriene and betamethasone dipropionate

  • DrugVehicle

    vehicle foam applied to affected areas once daily

  • DrugOtezla

    Otezla 30mg

06

What researchers measure

Primary outcomes

  1. Percent of Subjects With a Psoriasis Assessment and Severity Index (PASI) 75 at Week 16

    PASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0(no disease) to 72(maximal disease.) The body is divided into 4 sections: head (10% of total body surface area,) arms (20%,) trunk(30%,) and legs (40%.) Each of these is scored by itself and the 4 scores then combined to obtain thePASI. For each body area, the percent of skin area involved is estimated and graded based on this value (0=0% of area involved, 1=\<10%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89%, 6=90-100%.) Within each area, the severity of disease is based on 3 clinical signs: erythema or redness, induration or thickness, and desquamation or scaliness. Each is graded on a scale from 0(none) to 4(maximum.) The sum of all 3 parameters is calculated for each body section, multiplied by the area score for that section and then multiplied by the weight of that section (.1for head, .2 arms, .3 trunk and .4 legs)

    Time frame: 16 weeks

Secondary outcomes

  1. Percent of Subjects With PASI 75 at Week 4 and Week 12

    Psoriasis Area \& Severity Index (PASI) is a tool used to measure the severity of psoriasis. It combines the assessment of the severity of lesions and the area affected into a single score ranging from 0(no disease) to 72(maximal disease.)

    Time frame: 4 weeks, 12 weeks

  2. Percent of Subjects With PASI 90 and 100 at Week 16

    Psoriasis Area \& Severity Index (PASI) is a tool used to measure the severity of psoriasis. It combines the assessment of the severity of lesions and the area affected into a single score ranging from 0(no disease) to 72(maximal disease.)

    Time frame: 16 weeks

  3. Per Cent of Patients With at Least 1-grade Improvement in Physicians Global Assessment (PGA) at Week 4 and Week 12 and Week 16

    The Investigator will rate the severity of of disease based on the assessment of 3 clinical signs (erythema, induration, desquamation) wherein 0=no signs of psoriasis, 1=almost clear, 2=mild, 3=moderate, 4=severe

    Time frame: 4 weeks, 12 weeks, 16 weeks

  4. Global Improvement in Itch Visual Analogue Scale (VAS) at Week 4,12 and 16

    The Itch VAS (Visual Analog Scale) is completed by subjects wherein they are asked to rate the severity of their itching over the last 48 hours on a scale from 0 (no itching) to 10 (unbearable itching); low scores indicate a better outcome.

    Time frame: 4 weeks, 12 weeks, 16 weeks

  5. Global Percent Improvement in Dermatologic Quality of Life Index (DLQI) at Week 4, 12, and 16

    The DLQI is a 10-question tool completed by subjects to ascertain the severity of disease based on the extent to which disease interferes with daily life. Each question is scored according to the response wherein Very Much =3, A lot=2, A little=1 and Not at all=0. The sum of all responses is then recorded on a scale from 0 to 30, lower scores indicating better quality of life.

    Time frame: 4 weeks, 12, weeks, 16 weeks

07

Results

Posted Mar 13, 2019

Participant flow

Participant flow — Overall Study
MilestoneOtezla Plus Enstilar FoamOtezla Plus Vehicle Foam
Started1414
Completed1310
Not completed14
Withdrew: Withdrawal by subject11
Withdrew: Adverse event01
Withdrew: Protocol violation01
Withdrew: Lost to follow-up01

Outcome measures

PrimaryPercent of Subjects With a Psoriasis Assessment and Severity Index (PASI) 75 at Week 16

PASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0(no disease) to 72(maximal disease.) The body is divided into 4 sections: head (10% of total body surface area,) arms (20%,) trunk(30%,) and legs (40%.) Each of these is scored by itself and the 4 scores then combined to obtain thePASI. For each body area, the percent of skin area involved is estimated and graded based on this value (0=0% of area involved, 1=\<10%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89%, 6=90-100%.) Within each area, the severity of disease is based on 3 clinical signs: erythema or redness, induration or thickness, and desquamation or scaliness. Each is graded on a scale from 0(none) to 4(maximum.) The sum of all 3 parameters is calculated for each body section, multiplied by the area score for that section and then multiplied by the weight of that section (.1for head, .2 arms, .3 trunk and .4 legs)

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Percent of Subjects With a Psoriasis Assessment and Severity Index (PASI) 75 at Week 16
ParticipantsOtezla Plus Enstilar FoamOtezla Plus Vehicle Foam
Percent of Subjects With a Psoriasis Assessment and Severity Index (PASI) 75 at Week 1672
SecondaryPercent of Subjects With PASI 75 at Week 4 and Week 12

Psoriasis Area \& Severity Index (PASI) is a tool used to measure the severity of psoriasis. It combines the assessment of the severity of lesions and the area affected into a single score ranging from 0(no disease) to 72(maximal disease.)

Time frame:
4 weeks, 12 weeks
Reported as:
Count of participants · Participants
Percent of Subjects With PASI 75 at Week 4 and Week 12
ParticipantsOtezla Plus Enstilar FoamOtezla Plus Vehicle Foam
week 471
week 1242
SecondaryPercent of Subjects With PASI 90 and 100 at Week 16

Psoriasis Area \& Severity Index (PASI) is a tool used to measure the severity of psoriasis. It combines the assessment of the severity of lesions and the area affected into a single score ranging from 0(no disease) to 72(maximal disease.)

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Percent of Subjects With PASI 90 and 100 at Week 16
ParticipantsOtezla Plus Enstilar FoamOtezla Plus Vehicle Foam
PASI 9042
PASI 10010
SecondaryPer Cent of Patients With at Least 1-grade Improvement in Physicians Global Assessment (PGA) at Week 4 and Week 12 and Week 16

The Investigator will rate the severity of of disease based on the assessment of 3 clinical signs (erythema, induration, desquamation) wherein 0=no signs of psoriasis, 1=almost clear, 2=mild, 3=moderate, 4=severe

Time frame:
4 weeks, 12 weeks, 16 weeks
Reported as:
Count of participants · Participants
Per Cent of Patients With at Least 1-grade Improvement in Physicians Global Assessment (PGA) at Week 4 and Week 12 and Week 16
ParticipantsOtezla Plus Enstilar FoamOtezla Plus Vehicle Foam
week 4 — clear10
week 4 — almost clear51
week 4 — mild74
week 4 — moderate19
week 4 — severe00
week 12 — clear10
week 12 — almost clear13
week 12 — mild54
week 12 — moderate67
week 12 — severe10
week 16 — clear11
week 16 — almost clear81
week 16 — mild43
week 16 — moderate09
week 16 — severe10
SecondaryGlobal Improvement in Itch Visual Analogue Scale (VAS) at Week 4,12 and 16

The Itch VAS (Visual Analog Scale) is completed by subjects wherein they are asked to rate the severity of their itching over the last 48 hours on a scale from 0 (no itching) to 10 (unbearable itching); low scores indicate a better outcome.

Time frame:
4 weeks, 12 weeks, 16 weeks
Reported as:
Mean · scale unit
Global Improvement in Itch Visual Analogue Scale (VAS) at Week 4,12 and 16
scale unitOtezla Plus Enstilar FoamOtezla Plus Vehicle Foam
week 42 ± 25 ± 3
week 124 ± 34 ± 3
week 163 ± 34 ± 3
SecondaryGlobal Percent Improvement in Dermatologic Quality of Life Index (DLQI) at Week 4, 12, and 16

The DLQI is a 10-question tool completed by subjects to ascertain the severity of disease based on the extent to which disease interferes with daily life. Each question is scored according to the response wherein Very Much =3, A lot=2, A little=1 and Not at all=0. The sum of all responses is then recorded on a scale from 0 to 30, lower scores indicating better quality of life.

Time frame:
4 weeks, 12, weeks, 16 weeks
Reported as:
Mean · score on a scale
Global Percent Improvement in Dermatologic Quality of Life Index (DLQI) at Week 4, 12, and 16
score on a scaleOtezla Plus Enstilar FoamOtezla Plus Vehicle Foam
week 42 ± 25 ± 4
week 125 ± 55 ± 4
week 163 ± 46 ± 6

Adverse events

Collected over screening to week 16. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Otezla Plus Enstilar Foam0/14 (0%)1/14 (7.1%)5/14 (35.7%)
Otezla Plus Vehicle Foam0/14 (0%)0/14 (0%)9/14 (64.3%)
Most frequent serious events
Most frequent serious events
EventOtezla Plus Enstilar FoamOtezla Plus Vehicle Foam
sinus tachycardiaCardiac disorders1/140/14
upper respiratory infectionInfections and infestations1/140/14
chronic obstructive pulmonary disease exacerbationRespiratory, thoracic and mediastinal disorders1/140/14
thrombocytopeniaBlood and lymphatic system disorders1/140/14
shortness of airRespiratory, thoracic and mediastinal disorders1/140/14
Most frequent other events
Showing 10 of 26
Most frequent other events
EventOtezla Plus Enstilar FoamOtezla Plus Vehicle Foam
rhinorrheaRespiratory, thoracic and mediastinal disorders2/140/14
upper respiratory infectionRespiratory, thoracic and mediastinal disorders1/142/14
increased joint pain generalizedMusculoskeletal and connective tissue disorders1/141/14
chest congestionRespiratory, thoracic and mediastinal disorders1/140/14
squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/140/14
overactive bladderRenal and urinary disorders1/140/14
dyspnea at restRespiratory, thoracic and mediastinal disorders1/140/14
fall at homeGeneral disorders1/140/14
hypertensionCardiac disorders0/141/14
compressed lumbar discMusculoskeletal and connective tissue disorders0/141/14

Baseline characteristics

Age, Continuous
Age, Continuous(years)Otezla Plus Enstilar FoamOtezla Plus Vehicle FoamTotal
Mean55 ± 1752 ± 1253 ± 14
Sex: Female, Male
Sex: Female, Male(Participants)Otezla Plus Enstilar FoamOtezla Plus Vehicle FoamTotal
Female459
Male10919
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Otezla Plus Enstilar FoamOtezla Plus Vehicle FoamTotal
Hispanic or Latino000
Not Hispanic or Latino141428
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Otezla Plus Enstilar FoamOtezla Plus Vehicle FoamTotal
United States141428
08

Study locations

4 sites
  • Center for Dermatology and Laser Surgery
    Sacramento, California 95819, United States
  • Skin Sciences, PLLC
    Louisville, Kentucky 40217, United States
  • Lawrence J. Green, MD LLC
    Rockville, Maryland 20850, United States
  • Dermatology & Laser Center of Charleston
    Charleston, South Carolina 29414, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Oct 2018, 12 months.

Results were first posted in Mar 2019, 5 months after primary completion.

Of 75 non-industry phase 4 interventional studies under Psoriasis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's 12 months is below that.

Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2018
First posted
Feb 22, 2018
StartActual
Sep 18, 2017
Primary completionActual
Oct 1, 2018
CompletionActual
Oct 22, 2018
Results first posted
Mar 13, 2019
Last update
Mar 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03441789
Lead sponsor
L.H. Kircik, M.D.
Responsible party
L.H. Kircik, M.D. (Medical Director, Derm Research, PLLC) — Sponsor-investigator
First posted
Feb 22, 2018
Start date
Sep 18, 2017
Primary completion
Oct 1, 2018
Completion
Oct 22, 2018
Results posted
Mar 13, 2019
Last update
Mar 14, 2019

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion